Affordable Access

Access to the full text

Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives

Authors
  • Rahmani, Soheila1
  • Abdollahi, Mohammad1, 2
  • 1 Tehran University of Medical Sciences, Toxicology and Diseases Group, Pharmaceutical Sciences Research Center, Tehran, Iran , Tehran (Iran)
  • 2 Tehran University of Medical Sciences, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran, Iran , Tehran (Iran)
Type
Published Article
Journal
Archives of Toxicology
Publisher
Springer-Verlag
Publication Date
Oct 10, 2017
Volume
91
Issue
12
Pages
3717–3735
Identifiers
DOI: 10.1007/s00204-017-2086-7
Source
Springer Nature
Keywords
License
Yellow

Abstract

Sulfur mustard (SM), also known as mustard gas, is a chemical weapon which by now has been used in many wars. The most concerning SM toxic effect is probable carcinogenicity. In this study, the genetic and epigenetic mechanisms of SM carcinogenicity, by focusing on treatment of SM-associated malignancies, particularly gene therapeutics, cancer vaccines, and epigenetic medications, have been criticized. The required data were collected through an organized search on valid scientific databases. For SM carcinogenicity due to acute or chronic exposure, the entire original and review articles were evaluated. In addition, studies on the therapeutic effects of available genetic and epigenetic medications were included. Currently, four gene therapeutics, two cancer vaccines with genetic bases, and seven epigenetic medications are available for cancer treatment. Genetic and epigenetic cancer treatments including Gendicine, Imlygic, Provenge, Cimavax-EGF, Azacitidine, Vorinostat, Romidepsin, and Belinostat will yield outstanding benefits for SM-exposed patients who suffer from cancer.

Report this publication

Statistics

Seen <100 times